Sitravatinib plus tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic non-small cell lung cancer (NSCLC)

Gao, B; Ma, Z; Yu, X; Huang, D; Zhao, J; Day, D; Body, AL; Zhou, Q; Chu, Q; Pan, H; Cui, J; Li, H; Sun, J; Zhang, J; Fei, C; Wu, YL

ANNALS OF ONCOLOGY, 2022; 33 (): S1

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索